- Home
- CYCC
as 12-18-2024 4:00pm EST
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 2.3M | IPO Year: | N/A |
| Target Price: | $11.00 | AVG Volume (30 days): | 431.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.32 - $4.00 | Next Earning Date: | 11-12-2024 |
| Revenue: | $74,000 | Revenue Growth: | -80.98% |
| Revenue Growth (this year): | -87.13% | Revenue Growth (next year): | 88.68% |
Latest Cyclacel Pharmaceuticals Inc. News
CYCC Breaking Stock News: Dive into CYCC Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Simply Wall St.
a month ago
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Zacks
a month ago
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
GlobeNewswire
a month ago
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
GlobeNewswire
2 months ago
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Compare CYCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYCC Cyclacel Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.